IL2 and neoplasm: Consequently, the downregulated c-Myc fails to regulate IL-2/12-stimulated NK cell metabolic reprogramming (including the upregulation of glycolysis) and thus impairs NK cells’ antitumor capacity, which perpetuates tumor progression (117).